AptaBio is a South Korean pharmaceutical company at the forefront of discovery and development of selective inhibitors of the NOX family of enzymes and aptamer-based anti-cancer drugs.
AptaBio's unique and proprietary assay platform supports the screening and design of novel molecules against new targets.
AptaBio's NOX inhibitors include the 'first-in-class' candidate, APX-115 against diabetic nephropathy, APX-1004 against diabetic retinopathy, and APX-311 against NASH (non-alcoholic steatohepatitis). AptaBio's aptamer drug conjugates include APTA-12 (nuc-gemcitabine) for the treatment of solid tumors and APTA-16 for AML (acute myeloid leukemia).